Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus
Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025.
Sana Biotechnology Gets FDA Fast Track Designation for SC291 Cell Therapy
The U.S. Food and Drug Administration gave SC291, a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform, fast track designation, a process designed to facilitate the ...
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
Fast Track designation is designed to expedite clinical development and regulatory review timelinesEnrolling patients in the GLEAM trial for ...
manilatimes2d
Vancouver Canucks Hockey Team Announces Fortinet as Its "Preferred Partner,” Selects Fortinet Security Fabric Platform and Secure SD-WAN
NHL Vancouver Canucks and Fortinet ® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, today announced that Fortinet has become the new Preferred ...
Business Insider2d
Sana Biotechnology announces Fast Track designation for SC291
Sana Biotechnology (SANA) announced that the U.S. Food and Drug Administration granted Fast Track designation for SC291 in relapsed/refractory systemic lupus erythematosus, which includes extrarenal ...